title: The treatment of influenza with antiviral drugs.
abstract: Influenza vaccination with current inactivated vaccines homologous to the prevalent wild-type virus can reduce influenza illness in 75%-80% of healthy adults. Vaccine is recommended for all individuals with chronic underlying diseases and for those aged 65 years or older. Although influenza vaccination is still advocated for patients with blunted immunity, protection rates are not as high, running at 40% for frail institutionalized elderly people. The influenza antiviral agents amantadine or rimantadine, zanamivir and oseltamivir can modify the severity of illness and reduce the duration of illness by about 1.5-2.5 days. Amantadine inhibits only influenza A. Resistant virus may emerge in up to 33% of amantadine-treated patients in the first 5 days of treatment and be transmitted to susceptible close contacts. Side effects are usually mild in short courses of treatment. The neuraminidase inhibitor drugs zanamivir and oseltamivir act on both influenza A and B. Treatment is most effective when given within 30-36 hours after the onset of illness, and the earlier the better. Influenza should be treated with antiviral drugs in unvaccinated and vaccinated high-risk patients, as well as immunosuppressed patients with influenza-like illness, in periods of confirmed influenza prevalence. These drugs may be of great value in the event of a major viral antigenic shift that causes pandemic influenza, if an adequate supply can be sustained.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, BC. gstiver@interchange.ubc.ca
authors.forename: Grant
authors.initials: G
authors.lastname: Stiver
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007252:Influenza Vaccines / Q000627:therapeutic use*; D007251:Influenza, Human / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D009975:Orthomyxoviridae / Q000187:drug effects / Q000201:enzymology / Q000472:pathogenicity
chemical_list: D000998:Antiviral Agents; D007252:Influenza Vaccines; D000547:Amantadine